Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

NCT03292302 is registered in ClinicalTrials.gov with Eloxx Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03292302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03292302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 26, 2017
Completion date
December 15, 2017
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genetic disease, nonsense mutation